Thermo Fisher Scientific Inc. $TMO Shares Acquired by Jennison Associates LLC

Jennison Associates LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.2% during the 4th quarter, HoldingsChannel reports. The fund owned 277,111 shares of the medical research company’s stock after acquiring an additional 25,644 shares during the quarter. Jennison Associates LLC’s holdings in Thermo Fisher Scientific were worth $160,572,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Assetmark Inc. increased its holdings in Thermo Fisher Scientific by 22.9% in the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after buying an additional 7,023 shares during the last quarter. Cornerstone Investment Partners LLC bought a new position in shares of Thermo Fisher Scientific during the third quarter valued at approximately $41,393,000. Mackenzie Financial Corp grew its holdings in shares of Thermo Fisher Scientific by 29.4% during the third quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock valued at $134,130,000 after purchasing an additional 62,790 shares during the last quarter. VELA Investment Management LLC grew its holdings in shares of Thermo Fisher Scientific by 65.5% during the third quarter. VELA Investment Management LLC now owns 9,305 shares of the medical research company’s stock valued at $4,513,000 after purchasing an additional 3,683 shares during the last quarter. Finally, NEOS Investment Management LLC grew its holdings in shares of Thermo Fisher Scientific by 28.6% during the third quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company’s stock valued at $24,913,000 after purchasing an additional 11,415 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. This represents a 3.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,800 shares of company stock valued at $2,963,544 in the last quarter. Insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TMO. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Citigroup upped their target price on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a report on Friday, January 30th. Morgan Stanley reissued an “overweight” rating and issued a $620.00 price objective on shares of Thermo Fisher Scientific in a report on Monday. DZ Bank assumed coverage on Thermo Fisher Scientific in a report on Friday, March 27th. They issued a “buy” rating and a $610.00 price objective for the company. Finally, Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $623.05.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $467.38 on Thursday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99. The firm has a market capitalization of $173.69 billion, a price-to-earnings ratio of 25.59, a price-to-earnings-growth ratio of 2.07 and a beta of 0.97. The business has a 50 day simple moving average of $496.82 and a 200 day simple moving average of $548.19. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.83 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were given a dividend of $0.47 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date was Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.